Press coverage about Johnson & Johnson (NYSE:JNJ) has trended somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Johnson & Johnson earned a coverage optimism score of 0.19 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 46.6938677470014 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:

Johnson & Johnson (NYSE:JNJ) traded up 0.73% during mid-day trading on Wednesday, reaching $133.23. The company’s stock had a trading volume of 6,332,347 shares. Johnson & Johnson has a one year low of $109.32 and a one year high of $137.08. The stock has a market cap of $358.90 billion, a P/E ratio of 22.54 and a beta of 0.78. The firm’s 50 day moving average is $133.35 and its 200-day moving average is $125.64.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, topping the Zacks’ consensus estimate of $1.79 by $0.04. The business had revenue of $18.84 billion for the quarter, compared to analyst estimates of $18.94 billion. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The company’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same period last year, the company posted $1.74 earnings per share. Equities analysts expect that Johnson & Johnson will post $7.18 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 12th. Stockholders of record on Tuesday, August 29th will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.52%. The ex-dividend date of this dividend is Friday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 56.76%.

Several research analysts have recently commented on the company. BTIG Research downgraded Johnson & Johnson from a “neutral” rating to a “sell” rating and set a $110.00 price objective on the stock. in a report on Friday, July 21st. Atlantic Securities downgraded Johnson & Johnson from a “neutral” rating to an “underweight” rating and set a $113.00 price objective on the stock. in a report on Friday, July 21st. Alembic Global Advisors downgraded Johnson & Johnson from a “neutral” rating to an “underweight” rating in a report on Friday, July 21st. Zacks Investment Research downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Friday, July 21st. Finally, Credit Suisse Group assumed coverage on Johnson & Johnson in a report on Thursday, July 20th. They issued an “outperform” rating and a $148.00 price objective on the stock. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $133.72.

COPYRIGHT VIOLATION NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect Johnson & Johnson (NYSE:JNJ) Share Price” was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://www.dailypolitical.com/2017/08/09/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-johnson-johnson-nysejnj-share-price.html.

In related news, VP Dominic J. Caruso sold 82,591 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the transaction, the vice president now directly owns 226,693 shares of the company’s stock, valued at $30,993,466.96. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Paulus Stoffels sold 102,692 shares of Johnson & Johnson stock in a transaction that occurred on Monday, July 24th. The shares were sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the transaction, the vice president now directly owns 230,342 shares in the company, valued at $30,667,733.88. The disclosure for this sale can be found here. Company insiders own 0.19% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Insider Buying and Selling by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.